Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-derived mesenchymal stem cell conditioned medium for chronic pain
jRCT1051260047Recruiting
- Sponsor
- Stem Cell Clinic Tokyo
- Start
- Mar 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ACT-20-CM in chronic pain, sponsored by Stem Cell Clinic Tokyo. Primary endpoints: Patient-reported impact of pain on daily life, Pain pattern and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
ACT-20-CM
03
Conditions
chronic pain
Beyond the preview
Go deeper on jRCT1051260047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051260047.